Skip to main content

Table 1 Demographics of TransATAC and POLAR cohorts

From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

  TransATAC POLAR
POLAR RMH POLAR LUH Total POLAR (RMH + LUH)
Patient group Training Validation Total Cases Controls Total Cases Controls Total Cases Controls Total
Number of patients 634 314 948 114 105 219 133 70 203 247 175 422
Age at diagnosis, yearsa
 Mean, years 64 65 65 56 58 57 62 60 61 59 58 59
 Median, years 64 64 64 54 58 56 61 58 61 58 58 58
 Range, years 48–89 47–86 47–89 29–93 28–88 28–93 35–100 35–87 35–100 29–100 28–88 28–100
Tumour size
  < 2 cm 427 (67%) 207 (66%) 634 (67%) 40 (35%) 43 (41%) 83 (38%) 40 (30%) 27 (39%) 67 (33%) 80 (32%) 70 (40%) 150 (36%)
 2–5 cm 194 (31%) 101 (32%) 295 (31%) 63 (55%) 54 (51%) 117 (53%) 89 (67%) 40 (57%) 129 (64%) 152 (62%) 94 (54%) 246 (58%)
  > 5 cm 13 (2%) 6 (2%) 19 (2%) 11 (10%) 8 (8%) 19 (9%) 4 (3%) 3 (4%) 7 (3%) 15 (6%) 11 (6%) 26 (6%)
Grade
 1 177 (28%) 88 (28%) 265 (28%) 12 (11%) 14 (13%) 26 (12%) 9 (7%) 11 (16%) 20 (10%) 21 (9%) 25 (14%) 46 (11%)
 2 368 (58%) 169 (54%) 537 (57%) 48 (42%) 52 (50%) 100 (46%) 72 (54%) 35 (50%) 107 (53%) 120 (49%) 87 (50%) 207 (49%)
 3 89 (14%) 57 (18%) 146 (15%) 54 (47%) 39 (37%) 93 (42%) 52 (39%) 24 (34%) 76 (37%) 106 (43%) 63 (36%) 169 (40%)
Histological subtype
 IDC 492 (78%) 230 (73%) 722 (76%) 80 (70%) 75 (71%) 155 (71%) 104 (78%) 55 (79%) 159 (78%) 184 (74%) 130 (74%) 314 (74%)
 ILC 86 (14%) 60 (19%) 146 (15%) 22 (19%) 18 (17%) 40 (18%) 27 (20%) 15 (21%) 42 (21%) 49 (20%) 33 (19%) 82 (19%)
 Other 56 (9%) 24 (8%) 80 (8%) 12 (11%) 12 (11%) 24 (11%) 2 (2%) 0 (0%) 2 (1%) 14 (6%) 12 (7%) 26 (6%)
Nodal status
 Node negative 441 (70%) 224 (71%) 665 (70%) 60 (53%) 56 (53%) 116 (53%) 42 (32%) 29 (41%) 71 (35%) 102 (41%) 85 (49%) 187 (44%)
 1–3 positive nodes 136 (22%) 63 (20%) 199 (21%) 25 (22%) 34 (32%) 59 (27%) 54 (41%) 31 (44%) 85 (42%) 79 (32%) 65 (37%) 144 (34%)
 4 or more nodes 57 (9%) 27 (9%) 84 (9%) 29 (25%) 15 (14%) 44 (20%) 37 (28%) 10 (14%) 47 (23%) 66 (27%) 25 (14%) 91 (22%)
PgR
 Negative 114 (18%) 46 (15%) 160 (17%) 5 (4%) 7 (7%) 12 (5%) 25 (19%) 9 (13%) 34 (17%) 30 (%) 16 (%) 46 (11%)
 Positive 513 (81%) 268 (85%) 781 (82%) 20 (18%) 23 (22%) 43 (20%) 102 (77%) 56 (80%) 158 (78%) 122 (%) 79 (%) 201 (48%)
 Unknown 7 (1%) 7 (1%) 89 (78%) 75 (71%) 164 (75%) 6 (5%) 5 (7%) 11 (5%) 95 (%) 80 (%) 175 (41%)
NPI categorya
  ≤ 3.4 298 (47%) 140 (45%) 438 (46%) 25 (22%) 26 (25%) 51 (23%) 15 (11%) 13 (19%) 28 (14%) 40 (16%) 39 (22%) 79 (19%)
 3.4–5.4 281 (44%) 147 (47%) 428 (45%) 49 (43%) 50 (48%) 99 (45%) 77 (58%) 42 (60%) 119 (59%) 126 (51%) 92 (53%) 218 (52%)
  > 5.4 55 (9%) 27 (9%) 82 (9%) 40 (35%) 29 (28%) 69 (32%) 41 (31%) 15 (21%) 56 (28%) 81 (33%) 44 (25%) 125 (30%)
Endocrine therapya
 Tamoxifen only 301 (47%) 163 (52%) 464 (49%) 80 (70%) 72 (69%) 152 (69%) 96 (72%) 50 (71%) 146 (72%) 176 (71%) 122 (70%) 298 (71%)
 AI 333 (53%) 151 (48%) 484 (51%) 34 (30%) 33 (31%) 67 (31%) 37 (28%) 20 (29%) 57 (28%) 71 (29%) 53 (30%) 124 (29%)
Chemotherapya
 No 634 (100%) 314 (100%) 948 (100%) 54 (47%) 49 (47%) 103 (47%) 94 (71%) 55 (79%) 149 (73%) 148 (60%) 104 (59%) 252 (60%)
 Yes 0 0 0 60 (53%) 56 (53%) 116 (53%) 39 (29%) 15 (21%) 54 (27%) 99 (40%) 71 (41%) 170 (40%)
  1. Abbreviations: AI Aromatase inhibitor, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, PgR Progesterone receptor, NPI Nottingham Prognostic Index, RMH Royal Marsden Hospital, LUH Lund University Hospital, POLAR Molecular Predictors Of early versus LAte Recurrence in ER+ breast cancer
  2. a Denotes matching criteria in POLAR